🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "major milestone" in the fight against increasingly resistant strains of the pathogen, according to health experts.

An International Challenge

Cases of gonorrhoea are increasing worldwide, with data suggesting more than 82 million new cases per year. Particularly high rates are seen in Africa and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune step in the context of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options currently available.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The World Health Organization has designated it as a "critical concern". Ongoing monitoring found that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Secure Clearance

Zoliflodacin, also known as Nuzolvence, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to major issues, including infertility. Scientists anticipate that specific application of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, also received approval in close succession. This treatment, which is employed against UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to develop it.

“This approval marks a significant shift in the therapy of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

As per findings published in a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This puts it on an comparable level with the current standard treatment, which combines a dual-drug approach. The trial involved nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals treating patients have voiced positive views. The availability of a one-pill regimen of this kind is seen as a "game-changer" for public health efforts. This is considered essential to alleviate the strain of the infection for people and to prevent the spread of untreatable gonorrhoea worldwide.